Purevax RC

attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) / inactivated feline calicivirosis antigens (FCV 431 and G1 strains)

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

What is Purevax RC?

Purevax RC is a vaccine containing the following active substances:

  • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain);
  • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains).

Purevax RC is a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.

What is Purevax RC used for?

Purevax RC is used to vaccinate cats from the age of eight weeks against the following diseases:

  • feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus);
  • feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus).

The vaccine helps to reduce the symptoms of the diseases and also helps to reduce viral excretion in case of calicivirus infection.

After Purevax RC has been made up, 1 ml is injected under the skin. The first injection should be given in cats aged at least eight weeks, with a second injection three to four weeks later. If the cat has high levels of antibodies inherited from the mother, the first vaccination should be delayed until 12 weeks of age. The cat should be revaccinated for all components one year after the first vaccination course, then every year.

How does Purevax RC work?

Purevax RC is a vaccine. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against diseases. Purevax RC contains small amounts of weakened or killed viruses that cause the diseases listed above.

When a cat is given the vaccine, the immune system recognises the weakened or killed viruses as ‘foreign’ and makes antibodies against them. In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to the viruses. The antibodies will help to protect against the diseases caused by these viruses. When exposed to any of these viruses later in life, the cat will either not become infected or have a much less serious infection.

How has Purevax RC been studied?

The effectiveness of Purevax RC has been studied in several trials in laboratory conditions where cats were vaccinated and infected with virulent herpesvirus and calicivirus. In the field, the studies of Purevax RC looked at the basic vaccination schedule (two injections three to four weeks apart) and at the booster vaccination (only one injection). They included young and adult cats of various breeds, but not young kittens. The main measure of effectiveness was the level of antibodies in the blood against the viruses in the vaccine.

What benefit has Purevax RC shown during the studies?

In laboratory conditions Purevax RC was demonstrated to provide protection against the diseases listed above. In the field study of basic vaccination there was an increase in antibodies against feline rhinotracheitis herpesvirus and calicivirus infection. In the study looking at booster vaccination, antibody levels against rhinotracheitis herpesvirus and calicivirus infection remained stable at a high level or increased slightly.

What is the risk associated with Purevax RC?

Occasionally, cats will develop temporary apathy (loss of interest in surroundings) and anorexia (loss of appetite), as well as hyperthermia (elevated body temperature) lasting for one or two days. There may be a local reaction at the injection site, with slight pain on touching, itching or oedema (swelling), which disappears within one or two weeks. For a full list of the side-effects reported with Purevax RC, see the package leaflet. Purevax RC should not be used in pregnant cats.

What are the precautions for the person who gives the medicine or comes into contact with the animal?

In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the doctor.

Why has Purevax RC been approved?

The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Purevax RC exceed the risks for the active immunisation of cats aged eight weeks or older against the diseases listed above, and recommended that Purevax RC be given a marketing authorisation. The benefit-risk balance may be found in module 6 of this EPAR.

Other information about Purevax RC

The European Commission granted a marketing authorisation valid throughout the European Union for Purevax RC to Merial on 23 February 2005.

Name Language First published Last updated
Purevax RC : EPAR - Summary for the public BG = bălgarski 2008-03-14  
Purevax RC : EPAR - Summary for the public ES = español 2008-03-14  
Purevax RC : EPAR - Summary for the public CS = čeština 2008-03-14  
Purevax RC : EPAR - Summary for the public DA = dansk 2008-03-14  
Purevax RC : EPAR - Summary for the public DE = Deutsch 2008-03-14  
Purevax RC : EPAR - Summary for the public ET = eesti keel 2008-03-14  
Purevax RC : EPAR - Summary for the public EL = elliniká 2008-03-14  
Purevax RC : EPAR - Summary for the public EN = English 2008-03-14  
Purevax RC : EPAR - Summary for the public FR = français 2008-03-14  
Purevax RC : EPAR - Summary for the public IT = italiano 2008-03-14  
Purevax RC : EPAR - Summary for the public LV = latviešu valoda 2008-03-14  
Purevax RC : EPAR - Summary for the public LT = lietuvių kalba 2008-03-14  
Purevax RC : EPAR - Summary for the public HU = magyar 2008-03-14  
Purevax RC : EPAR - Summary for the public MT = Malti 2008-03-14  
Purevax RC : EPAR - Summary for the public NL = Nederlands 2008-03-14  
Purevax RC : EPAR - Summary for the public PL = polski 2008-03-14  
Purevax RC : EPAR - Summary for the public PT = português 2008-03-14  
Purevax RC : EPAR - Summary for the public RO = română 2008-03-14  
Purevax RC : EPAR - Summary for the public SK = slovenčina 2008-03-14  
Purevax RC : EPAR - Summary for the public SL = slovenščina 2008-03-14  
Purevax RC : EPAR - Summary for the public FI = suomi 2008-03-14  
Purevax RC : EPAR - Summary for the public SV = svenska 2008-03-14  

This EPAR was last updated on 23/02/2015 .

Authorisation details

Product details

Product details for Purevax RC
NamePurevax RC
Agency product numberEMEA/V/C/000091
Active substance

attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) / inactivated feline calicivirosis antigens (FCV 431 and G1 strains)

International non-proprietary name (INN) or common name

vaccine against feline viral rhinotracheitis and feline calicivirosis

Species Cats
Anatomical therapeutic chemical veterinary (ATCvet) codeQI06AH

Publication details

Publication details for Purevax RC
Marketing-authorisation holder

Merial

Revision9
Date of issue of marketing authorisation valid throughout the European Union23/02/2005

Contact address:

Merial
29 avenue Tony Garnier
69007 Lyon
France

Product information

Product information

15/01/2015  Purevax RC -EMEA/V/C/000091 -WS-0606

Name Language First published Last updated
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23
Purevax RC : EPAR - Product Information SV = svenska 2009-02-20 2015-02-23

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30
Purevax RC : EPAR - All Authorised presentations SV = svenska 2008-02-29 2013-01-30

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Active immunisation of cats aged eight weeks and older:

  • against feline viral rhinotracheitis to reduce clinical signs;
  • against calicivirus infection to reduce clinical signs and excretion.

Onsets of immunity have been demonstrated one week after primary vaccination course for rhinotracheitis and calicivirus components.

The duration of immunity is one year after the last (re-)vaccination.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Purevax RC : EPAR - Procedural steps taken and scientific information after authorisation SV = svenska 2008-02-29 2015-02-23

Initial marketing-authorisation documents

Name Language First published Last updated
Purevax RC : EPAR - Procedural steps taken before authorisation SV = svenska 2005-11-22  
Purevax RC : EPAR - Scientific Discussion SV = svenska 2005-11-22